Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Employees

391

Sector

Pharmaceuticals

Calendar

03-02 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
08/12/25	71.27 $	-0.50%	1,991,357
05/12/25	71.63 $	+0.13%	2,961,498
04/12/25	71.54 $	-0.06%	2,514,106
03/12/25	71.58 $	+0.06%	1,674,277
02/12/25	71.54 $	+0.27%	2,314,607

Delayed Quote Nasdaq, December 08, 2025 at 07:02 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

71.63USD

Average target price

74.00USD

Spread / Average Target

+3.31%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 19:16:59 08/12/2025 GMT			5-day change	1st Jan Change
71.26 ^USD	-0.52%		-0.10%	+145.12%

11-20	Novartis Maintains Growth Targets, Lifts Peak Sales Outlook for Kisqali, Scemblix	MT
11-20	Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s -- Update	DJ

Capitalization	10.79B 9.29B 8.72B 8.11B 14.94B 973B 16.3B 102B 39.36B 459B 40.51B 39.64B 1,683B	P/E ratio 2025 *	-16x	P/E ratio 2026 *	-14.5x
Enterprise value	10.57B 9.09B 8.54B 7.94B 14.63B 952B 15.96B 99.49B 38.52B 450B 39.65B 38.8B 1,648B	EV / Sales 2025 *	520x	EV / Sales 2026 *	523x
Free-Float	95.17%	Yield 2025 *	-	Yield 2026 *	-

11-20	Novartis Maintains Growth Targets, Lifts Peak Sales Outlook for Kisqali, Scemblix	MT
11-20	Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s -- Update	DJ
11-20	Novartis Expects Steady Sales Growth Through 2030	DJ
11-20	Novartis sees sales boost from key cancer drugs	RE
11-20	Novartis forecasts 2025-2030 sales CAGR of +5-6% CC	RE
11-19	Avidity Biosciences, Inc. Announces U.S. Managed Access Program for Investigational Therapy Del-Zota in DMD44	CI
11-19	Avidity Biosciences announces U.S. Managed Access Program (MAP) for investigational therapy del-zota in DMD44	RE
11-10	Avidity Biosciences reports wider-than-expected Q3 net loss	RE
11-10	Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Chardan Downgrades Avidity Biosciences to Neutral From Buy	MT
10-29	Wolfe Research Downgrades Avidity Biosciences to Peer Perform From Outperform	MT
10-29	TD Cowen Downgrades Avidity Biosciences to Hold From Buy, Adjusts Price Target to $74 From $78	MT
10-28	Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead -- 2nd Update	DJ

11-07	Chardan Downgrades Avidity Biosciences to Neutral From Buy	MT
10-29	Wolfe Research Downgrades Avidity Biosciences to Peer Perform From Outperform	MT
10-29	TD Cowen Downgrades Avidity Biosciences to Hold From Buy, Adjusts Price Target to $74 From $78	MT
10-28	Chardan Downgrades Avidity Biosciences to Neutral From Buy, Trims Price Target to $72 From $75	MT
10-28	RBC Downgrades Avidity Biosciences to Sector Perform From Outperform, Raises Price Target to $72 From $61, Keeps Speculative Risk	MT

Avidity Biosciences, Inc. Share Price

Equities

RNA

US05370A1088

Pharmaceuticals

Valuation: Avidity Biosciences, Inc.

Chart: Avidity Biosciences, Inc.

Latest news: Avidity Biosciences, Inc.

Last Transcript: Avidity Biosciences, Inc.

Analysts' recommendations: Avidity Biosciences, Inc.

Press Releases: Avidity Biosciences, Inc.

News in other languages: Avidity Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Avidity Biosciences, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-20	Pharma giant Novartis aims for strong growth thanks to cancer treatments	AQ
11-20	Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44	AQ
11-19	Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44	PR
11-10	Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights	PR
10-28	Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders	PR

11-20	Novartis setzt für künftiges Wachstum auf zahlreiche neue Blockbuster
11-20	Novartis vise un CA à +5-6% par an jusqu'en 2030 avec les médicaments anticancéreux
11-20	Novartis erwartet dank Blockbustern weiterhin kräftiges Wachstum
11-20	Novartis rechnet mit stabilem Umsatzwachstum bis 2030
11-20	Novartis étend mais modère ses visées de croissance à moyen-terme

1 day	-0.54%
1 week	-0.10%
Current month	-0.59%
1 month	+2.06%
3 months	+48.35%
6 months	+118.25%
Current year	+145.12%

1 week	71.12	71.79
1 month	69.77	71.79
Current year	21.51	71.79
1 year	21.51	71.79
3 years	4.82	71.79
5 years	4.82	71.79
10 years	4.82	71.79

Manager	Title	Age	Since
Sarah Boyce CEO	Chief Executive Officer	53	30/09/2019
Michael MacLean DFI	Director of Finance/CFO	59	18/05/2020
Charles Calderaro CTO	Chief Tech/Sci/R&D Officer	61	31/12/2024

Director	Title	Age	Since
Troy Wilson CHM	Chairman	56	12/11/2012
Arthur Levin BRD	Director/Board Member	71	22/02/2023
Noreen Henig BRD	Director/Board Member	60	21/08/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AVIDITY BIOSCIENCES, INC.	-0.52%	-0.10%	+93.43%	+528.57%	10.79B
REGENERON PHARMACEUTICALS, INC.	-1.55%	-5.84%	-10.37%	-7.73%	73.7B
CSL LIMITED	+0.76%	-0.43%	-33.94%	-38.00%	58.94B
UCB	+0.28%	+3.59%	+36.37%	+242.06%	54.7B
SAMSUNG BIOLOGICS CO.,LTD.	-0.73%	+62.90%	+62.90%	+62.90%	51.57B
BIOGEN INC.	-0.41%	+1.51%	+15.35%	-37.58%	26.6B
INNOVENT BIOLOGICS, INC.	-6.96%	-9.03%	+126.46%	+210.14%	20.25B
INCYTE CORPORATION	-3.77%	-3.71%	+36.25%	+16.81%	20.13B
ALTEOGEN INC.	+0.33%	-14.07%	+49.67%	+1,088.07%	16.58B
BRIDGEBIO PHARMA, INC.	+1.22%	+3.08%	+150.81%	+675.58%	14.19B
Average	-1.15%	-2.22%	+52.69%	+274.08%	34.75B
Weighted average by Cap.	-0.88%	-2.40%	+29.18%	+145.63%

	2025 *	2026 *
Net sales	20.33M 17.5M 16.43M 15.27M 28.15M 1.83B 30.71M 191M 74.14M 865M 76.31M 74.67M 3.17B	19.34M 16.65M 15.63M 14.53M 26.77M 1.74B 29.21M 182M 70.51M 823M 72.57M 71.02M 3.02B
Net income	-616M -530M -497M -462M -852M -55.49B -930M -5.8B -2.24B -26.2B -2.31B -2.26B -95.99B	-716M -616M -578M -537M -991M -64.5B -1.08B -6.74B -2.61B -30.46B -2.69B -2.63B -112B
Net Debt	-228M -196M -184M -171M -315M -20.53B -344M -2.14B -830M -9.69B -855M -836M -35.51B	-688M -593M -556M -517M -953M -62.06B -1.04B -6.48B -2.51B -29.3B -2.58B -2.53B -107B